Buchumschlag

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Considerations for Outcome Measurement and Clinical Interpretation

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Dingsheng Liu, Banghua Zhong, Lili Guo
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Critical Considerations for Outcome Measurement and Clinical Interpretation. Authors' Reply
von: Jeffrey D. McCurdy, et al.
Veröffentlicht: (2025)

Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply
von: Jeffrey D McCurdy, et al.
Veröffentlicht: (2025)

Systematic Review of Published Guidelines: Recommendations for Exams Under Anaesthesia, Seton Insertion and Timing of Seton Removal for Perianal and Rectovaginal Fistulising Crohn's Disease
von: Edgard Medawar, et al.
Veröffentlicht: (2026)

Editorial: Upadacitinib in Perianal Crohn's Disease
von: Manjeet Kumar Goyal, et al.
Veröffentlicht: (2026)

Editorial: Examining Perianal Fistulising Crohn's Disease Through the Lens of Wound Repair
von: Tim Eglinton
Veröffentlicht: (2025)

Letter: Putting Crohn's Risk Prediction to Work in Perianal Fistula—Calibration, Thresholds, and Transport
von: Emmanuel Pio Pastore
Veröffentlicht: (2025)

Editorial: Mesenchymal Stem Cell Therapy for Perianal Fistulising Crohn's Disease—Effective or Hype?
von: Jeffrey D McCurdy, et al.
Veröffentlicht: (2024)

Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulizing Crohn's Disease
von: Runqi Wang, et al.
Veröffentlicht: (2026)

One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study
von: Nicolas Richard, et al.
Veröffentlicht: (2026)

Editorial: Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulising Crohn's Disease. Authors' Reply
von: Runqi Wang, et al.
Veröffentlicht: (2026)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
von: Tamar Schildkraut, et al.
Veröffentlicht: (2024)

Editorial: Development and Validation of a Multimodal Machine Learning Model for Diagnosing and Assessing Risk of Crohn's Disease in Patients With Perianal Fistula
von: Alyssa M. Parian, et al.
Veröffentlicht: (2025)

Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
von: Zhidong Zhou, et al.
Veröffentlicht: (2025)

Letter: ‘Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study’
von: Matthias Kelm, et al.
Veröffentlicht: (2025)

Letter: Crohn's Disease or Comorbidity? Reassessing Opioid Prescribing Patterns
von: Kuan‐Ju Lin, et al.
Veröffentlicht: (2025)

Editorial: Development and Validation of a Multimodal Machine Learning Model for Diagnosing and Assessing Risk of Crohn's Disease in Patients With Perianal Fistulae: Authors' Reply
von: Lichao Qiao, et al.
Veröffentlicht: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
von: Virginia Solitano, et al.
Veröffentlicht: (2024)

Letter: Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study: Authors' Reply
von: Nathan Grellier, et al.
Veröffentlicht: (2025)

Letter: The Simple Endoscopic Score for Predicting Crohn's Disease Progression—Not as Simple as It Sounds
von: Ziheng Calvin Xu, et al.
Veröffentlicht: (2025)

Correction to ‘Stromal Vascular Fraction With Platelet‐Rich Plasma Injection During Surgery is Feasible and Safe in Treatment‐Refractory Perianal Fistulising Crohn's Disease: A Pilot Study’
Veröffentlicht: (2024)

Letter: Are Antispasmodics Truly Ineffective in IBD? Considerations on Nuanced Interpretation and Stratified Analysis. Authors' Reply
von: Chachrit Khunsriraksakul, et al.
Veröffentlicht: (2025)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR
von: Zhejin Shi, et al.
Veröffentlicht: (2026)

Letter: Amino Acid Imbalance and Mortality in Cirrhosis—Interpretation and Methodological Considerations. Authors' Reply
von: Yuki Utakata, et al.
Veröffentlicht: (2026)

Letter: Dynamic HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation: Considerations in Interpreting Predictive Performance
von: Hsiang‐Ting Keng, et al.
Veröffentlicht: (2026)

Letter: Crohn's Disease With Latent Tuberculosis Infection or Intestinal Tuberculosis: Rapid Discrimination by Targeted Next‐Generation Sequencing
von: Maryam Irshad, et al.
Veröffentlicht: (2025)

Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease
von: Jiacheng Li
Veröffentlicht: (2026)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
von: Yu‐Sheng Lin, et al.
Veröffentlicht: (2026)

Network Meta‐Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease
von: Mohammad Shehab, et al.
Veröffentlicht: (2025)

Letter: Beyond Survival Benefit in CHANCE2311—Important Considerations in the Interpretation of TACE Combined With Immunotherapy in Advanced HCC
von: Yinghan Chen, et al.
Veröffentlicht: (2026)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients With Inflammatory Bowel Disease
von: Chang Liu, et al.
Veröffentlicht: (2026)

Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease. Authors' Reply
von: José Luis Rueda García, et al.
Veröffentlicht: (2026)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations
von: Christophe Corpechot
Veröffentlicht: (2026)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations. Authors' Reply
von: Mohamed El‐Kassas, et al.
Veröffentlicht: (2025)

Letter: Methodological Considerations in Comparing Liver Outcomes of Glucagon‐Like Peptide‐1 Receptor and Sodium Glucose Cotransporter‐2 Inhibitors
von: Cheng‐Hsien Hung, et al.
Veröffentlicht: (2025)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations
von: Jiru Li, et al.
Veröffentlicht: (2025)

Letter: From Descriptive Epidemiology to Clinical Imperative—Challenging the Paradigm of Pain and Sedative Use in Inflammatory Bowel Disease
von: DuJiang Yang, et al.
Veröffentlicht: (2025)

Letter: Gut microbiota—An overlooked therapeutic target in the prevention of post‐operative recurrence of Crohn's disease
von: D. Bogatic, et al.
Veröffentlicht: (2024)

Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises the Importance of Appropriate Patient Selection and Centre Expertise
von: Weilun Gao, et al.
Veröffentlicht: (2024)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations. Authors' Reply
von: J. M. Schattenberg, et al.
Veröffentlicht: (2026)

Letter: Extreme diagnostic delay due to misdiagnosis of gastrointestinal tuberculosis later diagnosed as postoperative Crohn's disease
von: Abhirup Chatterjee, et al.
Veröffentlicht: (2024)